A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Pfizer
City of Hope Medical Center
Novartis
City of Hope Medical Center
Tempus AI